Does Monoamine Oxidase Inhibitors Maois Interact with Valbenazine?
CDI records a contraindicated classification for Monoamine Oxidase Inhibitors Maois and Valbenazine. The stored summary is: Concomitant use may increase monoamine neurotransmitter concentration in synapses, potentially leading to serotonin syndrome or attenuated treatment effect. Avoid use or within 14 days of discontinuing MAOI therapy. The mechanism involves increased concentration of monoamine neurotransmitters in synapses. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increased concentration of monoamine neurotransmitters in synapses
What To Tell Your Doctor or Pharmacist
If you are taking Monoamine Oxidase Inhibitors Maois and your doctor is considering prescribing Valbenazine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider